{'fraction_non_alphanumeric': 0.0331925165962583, 'fraction_numerical': 0.011466505733252867, 'mean_word_length': 5.118081180811808, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dapagliflozin effect on heart failure with prevalent or new‐onset atrial fibrillation

This article refers to ‘Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF’ by J.H. Butt et al. , published in this issue on pages 5 1 3–525. Heart failure (HF) and atrial fibrillation (AF) are both heteroge-neous conditions that affect millions of people worldwide. 1 The overlap of clinical risk factors suggests that there may be similarities in remodelling processes ongoing in the heart. 1 Advances in therapies have substantially improved the prognosis of HF patients with reduced ejection fraction (HFrEF) and AF separately, where treatment options in HF with preserved ejection fraction (HFpEF) are still limited. 2,3 Nonetheless, mortality persists high in both HFrEF and HFpEF, especially when combined with AF. 1 ,2 Therefore, new therapies targeting patients with the combination of HF and AF are eagerly needed. Sodium–glucose co-transporter type 2 (SGLT2) inhibitors, developed as a lowering-glucose therapy, were recently proven to prevent and treat HF. 4 In the current issue of the Journal, Butt and colleagues add in timely manner evidence of the beneficial effects of dapagliflozin, an SGLT2 inhibitor, on outcomes of both with the combination of HFrEF and AF. 5 The authors performed a sub-analysis of the DAPA-HF trial, and demonstrated that dapagliflozin, on top of guideline-recommended therapies, was as effective in patients with AF as compared to those without AF, to improve prognosis. In line with previous HF trials, approximately 40% of HFrEF patients had on electrocardiogram (ECG)